The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Alkermes plc (NASDAQ: ALKS) closed at $28.2 in the last session, down -1.43% from day before closing price of $28.61. In other words, the price has decreased by -$1.43 from its previous closing price. On the day, 2.47 million shares were traded. ALKS stock price reached its highest trading level at $28.63 during the session, while it also had its lowest trading level at $27.895.
Ratios:
We take a closer look at ALKS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.49. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Truist on November 11, 2025, initiated with a Buy rating and assigned the stock a target price of $50.
On September 26, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $44.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $44.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $44 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Hopkinson Craig C. sold 9,000 shares for $30.38 per share. The transaction valued at 273,442 led to the insider holds 69,740 shares of the business.
Hopkinson Craig C. bought 9,000 shares of ALKS for $273,442 on Nov 03 ’25. On Oct 15 ’25, another insider, Hopkinson Craig C., who serves as the EVP R&D, Chief Medical Officer of the company, sold 9,000 shares for $31.53 each. As a result, the insider received 283,776 and left with 73,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALKS now has a Market Capitalization of 4656313856 and an Enterprise Value of 3616797696. As of this moment, Alkermes’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.95, and their Forward P/E ratio for the next fiscal year is 17.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06 while its Price-to-Book (P/B) ratio in mrq is 2.69. Its current Enterprise Value per Revenue stands at 2.377 whereas that against EBITDA is 9.305.
Stock Price History:
The Beta on a monthly basis for ALKS is 0.51, which has changed by -0.021880329 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, ALKS has reached a high of $36.45, while it has fallen to a 52-week low of $25.17. The 50-Day Moving Average of the stock is -6.54%, while the 200-Day Moving Average is calculated to be -6.81%.
Shares Statistics:
According to the various share statistics, ALKS traded on average about 2.42M shares per day over the past 3-months and 3247220 shares per day over the past 10 days. A total of 165.10M shares are outstanding, with a floating share count of 161.42M. Insiders hold about 2.24% of the company’s shares, while institutions hold 104.03% stake in the company. Shares short for ALKS as of 1761868800 were 15896950 with a Short Ratio of 6.58, compared to 1759190400 on 15214415. Therefore, it implies a Short% of Shares Outstanding of 15896950 and a Short% of Float of 13.96.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is $0.38, with high estimates of $0.38 and low estimates of $0.38.
Analysts are recommending an EPS of between $2.22 and $1.43 for the fiscal current year, implying an average EPS of $1.93. EPS for the following year is $2.32, with 1.0 analysts recommending between $2.32 and $2.32.
Revenue Estimates
According to 15 analysts,. The current quarter’s revenue is expected to be $378.57M. It ranges from a high estimate of $400.84M to a low estimate of $357M. As of. The current estimate, Alkermes plc’s year-ago sales were $429.99MFor the next quarter, 15 analysts are estimating revenue of $378.72M. There is a high estimate of $418.92M for the next quarter, whereas the lowest estimate is $329.83M.
A total of 15 analysts have provided revenue estimates for ALKS’s current fiscal year. The highest revenue estimate was $1.49B, while the lowest revenue estimate was $1.45B, resulting in an average revenue estimate of $1.47B. In the same quarter a year ago, actual revenue was $1.56BBased on 11 analysts’ estimates, the company’s revenue will be $1.8B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.54B.
